Showing posts with label Fake science. Show all posts
Showing posts with label Fake science. Show all posts

The corruption of academic medicine

Many doctors are genuinely puzzled why much of the general public does not trust what they say. For example, there’s the GOOP story. Gwenyth Paltrow sells lots of scientifically iffy wellness products on her website, and there’s many doctors and ‘health professionals’ frothing at the mouth trying to ‘debunk’ her theories. But, in the end, GOOP is selling millions of dollars of product. The public has voted with its money, and it chooses Gwenyth over the doctors. Why?
Then, there’s the anti-vaxxers/ vaccine controversy. Once again, celebrities like Jenny McCarthy claim that vaccines cause autism. Many doctors are frothing at the mouth and loudly ‘debunking’ these theories. Despite these protestations, we have occasional mumps outbreaks where children have not been properly vaccinated. Again, the public has voted with its children, and it chooses Jenny over the doctors. Once again, why?

Why is it so difficult to tell the truth about statins?


Please watch this:

Statin Drugs from Terry Cotter on Vimeo.


She says:

1. You can lower LDL by 8-10% by diet.





2. She tries to fool people by using statistics....

At 32 seconds she says 'There are a lot of benefits'

OK grab a piece of paper and note down the benefits she identifies...

a. they reduce CVD deaths and events


Right...try reading this

She quotes studies - OK here's a major one:

https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0071769/

I quote:

Statin versus placebo, subgroup analysis by statin intensity

All-cause mortality
  • High quality evidence showed that statins are more effective when compared to placebo at reducing all-cause mortality at up to 6 years, but the effect size is too small to be clinically important [26 studies, n=120,329].
  • High quality evidence showed that low-intensity statins are more effective when compared to placebo at reducing all-cause mortality at up to 6 years, but the effect size is too small to be clinically important [12 studies, n=48,978].
  • High quality evidence showed that medium-intensity statins are more effective when compared to placebo at reducing all-cause mortality at up to 5 years, but the effect size is too small to be clinically important [8 studies, n=42,687].
  • High quality evidence showed that high-intensity statins are more effective when compared to placebo at reducing all-cause mortality at up to 5 years, but the effect size is too small to be clinically important [6 studies, n=27,664].
CV mortality
  • High quality evidence showed that statins are more effective when compared to placebo at reducing CV mortality at up to 6 years, but the effect size is too small to be clinically important [22 studies, n=118,938].
  • High quality evidence showed that low-intensity statins are more effective when compared to placebo at reducing CV mortality at up to 6 years, but the effect size is too small to be clinically important [11 studies, n=50,127].
  • High quality evidence showed that medium-intensity statins are more effective when compared to placebo at reducing CV mortality at up to 5 years, but the effect size is too small to be clinically important [7 studies, n=42,248].
  • Moderate quality evidence showed that high-intensity statins are more effective when compared to placebo at reducing CV mortality at up to 6 years, but the effect size is too small to be clinically important at up to 5 years, but the effect size is too small to be clinically important [4 studies, n=26,576].
Non-fatal MI
  • Moderate quality evidence showed that statins are more clinically more effective when compared to placebo at reducing non-fatal MI at up to 6 years [21 studies, n=91,482].
  • Moderate quality evidence suggested that there may be no clinical difference between low-intensity statins when compared placebo at reducing non-fatal MI at up to 6 years, but the direction of the estimate of effect favoured low-intensity statins [13 studies, n=40,589].
  • High quality evidence showed that medium-intensity statins are more clinically more effective when compared to placebo at reducing non-fatal MI at up to 5 years [4 studies, n=28,068].
  • High quality evidence showed that high-intensity statins are more clinically more effective when compared to placebo at reducing non-fatal MI at up to 5 years [4 studies, n=22,825].
Stroke
  • Moderate quality evidence suggested that there may be no clinical difference between statins when compared to placebo at reducing stroke at up to 6 years, but the direction of the estimate of effect favoured statins [19 studies, n=109,244].
  • High quality evidence showed that low-intensity statins are more effective when compared to placebo at reducing stroke at up to 6 years, but the effect size is too small to be clinically important [10 studies, n=44,310].
  • Moderate quality evidence suggested that medium-intensity statins are potentially more effective when compared to placebo at reducing stroke at up to 5 years [5 studies, n=38,350].
  • Moderate quality evidence suggested that there may be no clinical difference between high-intensity statins when compared to placebo at reducing stroke at up to 5 years, but the direction of the estimate of effect favoured high-intensity statins [4 studies, n=26,575].
Well - that's not very impressive!

53 seconds..."nothing we could do..."

What sort of incompetent is she?

a. DIET
b. EXERCISE
c. STRESS REDUCTION

All of these are within the skills of a health provider...

Impressive figures at 1.09...or not. BUT no mention is made of any changes in lifestyle.

If I have a heart attack or similar and someone gives me statins I STOP SMOKING, STOP THE BOOZE etc.

It is ridiculous to say the situation has not changed!!!

1.15: "I feel fine why do I have to take something"

Maybe people feel fine if they lose weight, sleep better, exercise more and thus STOP statins!

1,21: "20% have side effects but they're usually reversible"....over what time period? 20 years?

1.34: slide showing statin misconceptions.

Low risk of side effects...20% is LOW

Don't lower heart disease risk. 1% is acceptable?

Side effects outweigh benefits. They DO if you don't get the benefits!!!


Please go and look at it.

10% - 20% lower risk of CVD events or deaths.

That is at 1.52.

OK let's look and see what it really says....

Under LIMITATIONS

"Limitations:
The risk for recurrent adverse reactions to statins could not be established for the entire sample. It was also not possible to determine whether patients actually took the statins."
And this is 'research'?
Anyway, I digress. Look at the actual data:
" Four years after the presumed adverse event, the cumulative incidence of the composite primary outcome was 12.2% for patients with continued statin prescriptions, compared with 13.9% for those without them"
So 1.7% more people had events - could that have anything to do with a whole host of other risk factors or were they ALL excluded and statins isolated?
2.19 - the internet has done a disservice.
Read the above again and judge for yourself.
2.37 - diets have not been proven to work

Sigh... just google it...

2.45 - your diet is part of the equation

No contradiction then!




Fake science

Are studies tying red wine to health benefits nothing more than wishful thinking? Some red wine studies may soon be called into question following a report that a top researcher at the University of Connecticut falsified data on more than 100 occasions.
UConn officials conducted an internal review into the work of Dr. Dipak K. Das, director of the cardiovascular research center at the university, after the university received an anonymous tip. Das had been known in recent years for his research on the benefits of resveratrol, a compound found in red wine. Resveratrol is thought to work because it activates proteins called sirtuins that have been shown in studies to have protective benefits.
The officials found 145 cases of fabricated or false data and notified 11 journals - including the Journal of Cellular & Molecular Medicine and Journal of Agriculture and Food Chemistry - of its review, the university said in a written statement.
"We have a responsibility to correct the scientific record and inform peer researchers across the country," Philip Austin, interim vice president for health affairs, said in the statement.
As a result of UConn's three-year investigation that culminated in a 60,000 page report on the allegations, UConn has declined $890,000 in research grants and cut off external funding to the lab.
It's unclear at this time which studies contained falsified data, so wine aficionados can hold out hope that red wine might benefit a person's health.
The Connecticut Mirror reports that much of the research discrepancies centered on "western blot" figures, which illustrate specific proteins from tissue samples. The review showed these images may have been manipulated to combine data from other experiments, which were passed off as coming from a single experiment.
"Many figures had more manipulations but, for expediency, the review board only noted the most obvious," in flagging 145 cases of misconduct according, to the paper.
According to the research bibliography site PubMed, Das has served as a lead author or co-author on more than 150 articles, including a Jan. 2012 study titled, "Health benefits of wine and alcohol from neuroprotection to heart health," published in Frontiers in Bioscience.
Das' other areas of research besides resveratrol include medicines derived from plants and the molecular structure of plants and herbs and their effect on heart disease, according to the Associated Press.
Earlier reservatrol studies have suggested the compound might be"exercise in a bottle"in its ability to stave off the effects of a sedentary lifestyle, while other research has said the compound might reduce risk for skin cancer. According to the Mayo Clinic, some studies have showed resveratrol lowers levels of "bad" cholesterol and protects the lining of heart blood vessels.
In 2009, 60 Minutes' Morley Safer profiled potential benefits of resveratrol.
Some resveratrol researchers were not concerned by the fraud allegations and still believe the compound can improve longevity.
"I don't expect this news to have a big impact on what we work on," Dr. David Sinclair, a resveratrol researcher at the Harvard Medical School, told CBS News in an email. Sinclair had been featured in the 2009 60 Minutes report. Sinclair said his research focuses on sirtuins and aging, while a lot of the published research papers in question focused on heart health. 
"There is a comprehensive body of literature in mouse and rats indicating that resveratrol is effective in preventing numerous diseases in those animals, including type II diabetes, neurodegeneration, fatty liver, and inflammation, Sinclair said. "These results would not be in question, even if some of his work is retracted."

Fake science

When I was doing research in the field of echocardiography, and writing and publishing lots of research papers, there were only a few important cardiology journals that I wanted my papers published in.
It wasn’t easy getting my research published; after the paper was submitted, it was sent to two reviewers who critiqued it extensively and gave it  a thumbs up or down. Often, to satisfy the reviewers, I had to revise the manuscript multiple times, a process which could take months and months.
I knew once my work was published, however, that this heavy vetting process guaranteed that my paper appeared in a medium that was highly respected alongside similar important and well-vetted scientific work.
For the eighty-plus  papers that I published between 1987 and 1998, I paid not a dime, but I spent innumerable post-work hours reading, writing, and analyzing data.
In those years prior to the interweb, the process of researching a topic was laborious and time-consuming; I would spend hours in the medical libraries of various hospitals searching through the stacks of hard-bound medical journals for relevant articles. Once found, the very heavy tome containing the paper I needed would be lugged to a “Xerox” machine and copied.
I cannot recall one circumstance where a journal wrote to me asking me to submit a paper to them. The journals I published in were overwhelmed with high quality submissions from important scientists and only accepted a low percentage for publication.
The Rise of Open Access and Fake Scientific Journals
Unfortunately, we are now in an era of what I would term “fake scientific journals,” and in such journals it is quite easy to publish if one simply pays the asking price: somewhere between 150$ and 500$.
Publishers of these journals prey on scientists who are desperate to have their research published in order to survive in academia.
Jeffrey Beall, an academic librarian at the University of Colorado, Denver, noted the rise of this practice in 2008 and began researching what he termed “predatory journals.”  In a paper published in 2010 he wrote:
“These publishers are predatory because their mission is not to promote, preserve, and make available scholarship; instead, their mission is to exploit the author-pays, Open-Access model for their own profit.”
In 2012, Beall began listing (Beall’s list) predatory publishers and journals, and offered critical commentary on scholarly open-access publishing in a blog entitled  Scholarly Open Access.
Predatory journals have arisen in parallel with a change from print-only subscriptions to digitally available and free scientific publications.
It is important but often difficult to differentiate legitimate “open access” scientific journals from these profit-motivated sleazy journals.
A brief history of scientific publishing and the rationale for moving to open access publishing from Bowman:
Nature was first published in 1869, Science in 1880, and subsequently scientific journal publishing has increased to the point of a new paper being published every 20 seconds.1 In 2000, the future of scientific publishing was changed by the debut of PubMed Central and the Public Library of Science (PLoS). The next year, thousands of scientists called for a boycott of journals that would not allow free access on PubMed within 6 months. In 2002, for-profit Biomed Central began charging authors $500 to publish. In 2003, PLoS Biology was launched, charging authors $1500. By 2006, PLoS initiated the non-profit PLoS One, charged a $2500 author fee, and reviewed articles by placing scientific rigor over importance. In 2008, NIH mandated that papers published as a result of its funding be made free to the public within 12 months, and in 2009, the US Congress permanently required that all funded investigators submit electronic versions of their manuscripts to the National Library of Medicine’s PubMed Central.2 By 2010, PLoS generated revenues greater than costs and PLoS One became the world’s largest scientific publisher by volume.
My Brush With Fake Scientific Journals
From time to time since my days of research in academia, I have collaborated with medical residents at my hospital in writing what are termed “case reports.” These are descriptions of interesting patient cases and most prominent journals are not interested in publishing them.
However, I’ve noticed that with increasing frequency, I am receiving solicitations from journals I’ve never heard of based on my having published these types of papers.
Here’s my latest invitation. The editors of this journal (American Journal of Clinical and Experimental Medicine) first bizarrely ask me “how is everything going?”  then state that:
Your paper entitled Coronary Artery Fistula?\\Associated Endocarditis: Report of?Two Cases and a Review of the Literature from Echocardiography really attract us.
Are you interested in interested in sharing some other papers in this field?
If we may have the honor, we would like to publish your other papers in our journal.
Two weeks later they sent me a similar email with the verbiage slightly modified, but still horribly mangled:
We have learnt your paper entitled Coronary Artery Fistula?\\Associated Endocarditis: Report of?Two Cases and a Review of the Literature from Echocardiography, and are very attracted by its topic.
If you would like to publish other papers in the related subjects, you may consider to publish them in our journal
Both emails invited me to become a member of the editorial board!
How Can You Know Which Journals Are Fake?
Beginning in 2012, these types of journals were tracked by Beall’s list. In January 2017, Beall, “facing intense pressure from my employer, the University of Colorado Denver, and fearing for my job,” removed all of the blog contents from the internet.
(For a fascinating history of Beall’s work in this area see his article published here).
I found his list of predatory publishers resurrected  here.
Science Publishing Group, the publisher of  the journal that keeps emailing me is on the list.
A brief look at the website for Science Publishing Group does not reveal immediately that it is a predatory publisher. There are 80 scientific journals listed and they all have legitimate sounding names. However, I have never heard of any of them.
I searched in vain through the cardiology journals listed to find a paper that was the least bit interesting or important. Most of the listed editorial board members and authors were from third world countries. When I researched an American editorial board member  of one journal I found that he was a medical student.
Sting Operations on Fake Journals
Sting operations by academics have shown that papers that are composed of meaningless gobbledygook are often accepted by these types of journals as long as the publication fee is paid. The New Yorker has a great articledescribing such operations.
The Bohannon sting in Science two years ago found that 45% of a sample of publishers included in the directory of Open Access Journals accepted a bogus paper submitted for publication.
A recent sting operation also showed how anyone can become an editor or even “editor-in-chief” of one of these journals. From The NY times :
The applicant’s nom de plume was not exactly subtle, if you know Polish. The middle initial and surname of the author, Anna O. Szust, mean “fraudster.” Her publications were fake and her degrees were fake. The book chapters she listed among her publications could not be found, but perhaps that should not have been a surprise because the book publishers were fake, too.
Yet, when Dr. Fraud applied to 360 randomly selected open-access academic journals asking to be an editor, 48 accepted her and four made her editor in chief. She got two offers to start a new journal and be its editor. One journal sent her an email saying, “It’s our pleasure to add your name as our editor in chief for the journal with no responsibilities.”
Fake Conferences
Adding insult to scientific injury is the rise of fake scientific conferences.
I’ve been invited to lots of these important sounding conferences just based on publishing one case report. These emails are typically poorly written. If I didn’t know they were complete BS I would be flattered by the complements:
To ensure that you do not miss out, we extend our invitation to you again to express our sincere wish for your participation in BIT’s 9th Annual Congress of Cardiology-2017 (ICC-2017) with the theme of “Bridging Excellence in Cardiology and Clinical Aspects” will be held on 15-17 November 2017 in Singapore.
For your brilliant achievements and precious experience in the field of cardiology, on behalf of the organizing committee, we cordially welcome you to join us and give a presentation about Coronary Artery Fistula-Associated Endocarditis: Report of Two Cases and a Review of the Literature… at this congress.
I think I have had some brilliant achievements and my experiences are quite precious, but I’m definitely not  going to your ridiculous conference.
The Threat to Real Science
All of these fake and predatory scientific journals, editors and conferences could be dismissed as amusing if it weren’t for the fact that they are further contributing to the inability of the public to determine what is real science.
As Beall said
“predatory and low-quality journals are granting the imprimatur of science to basically any idea for which the author is willing to write an article and pay the author fees. This is polluting the scientific record with junk science”
This process is helping to fuel the rise of complementary and alternative medicine (CAM) which I have termed “fake medicine.” I’ve included below a long quote from Beall’s recent article which details this problem which he feels poses “the biggest threat to science since the Inquisition.”
Inquisitionally Yours,
-ACP
For your enjoyment, Beall’s full comments on the threat to science:
I think predatory publishers pose the biggest threat to science since the Inquisition. They threaten research by failing to demarcate authentic science from methodologically unsound science, by allowing for counterfeit science, such as complementary and alternative medicine (CAM) to parade as if it were authentic science, and by enabling the publication of activist science.
Because they aim to generate profits for their owners, gold (author-pays) open-access journals have a strong conflict-of-interest when it comes to peer review. They always want to earn money, and rejecting a paper means rejecting revenue. This conflict is at the heart of the ongoing downfall of scholarly publishing. Increasingly, the consumers of scholarly publishers’ services are the authors, not the readers, and not academic libraries. Businesses naturally always want to keep their customers content, for they want the revenue streams to continue and grow larger, as they add new services – such as more easy-acceptance journals – to their offerings.
Many of the larger predatory publishers, especially those based in Western Europe, offer a niche business. Their businesses are set up to publish manuscripts rejected by the top publishers, that is, papers rejected by Elsevier, Wiley, Sage, Taylor & Francis, Oxford University Press, and several others. They function something like a lender of last resort – they provide a publishing opportunity when no other publisher will, becoming, essentially, a Salon des Refusés for scholarly articles. However, the market is so lopsided now that there are more “publishers of last resort” than there are authentic ones, and they’re all competing with each other for subpar manuscripts.
Like counterfeit science itself, these publishers go through the motions of being a legitimate publisher. Some open-access publishers, even though they are not based in England, hire spokesmen with strong British accents to attend scientific conferences and other meetings and talk up the publisher, often renting a booth in the exhibit hall and even co-sponsoring some of the smaller meetings. They join publisher associations, make a show of donating to open-access causes, and manage to convince one or two aged Nobel Laureates to agree to serve on one of their editorial boards, no work required.
CAM is really taking off, and it’s being largely fuelled by pay-to-publish journals, though a few subscription journals have gotten in on the action as well. Predatory journals and even journals from legitimate publishers are legitimatizing this unscientific medical research in the public’s eye. Acupuncture and homeopathy are thriving, and numerous “studies” are being published each year to back up their effectiveness claims. In medicine, demarcation is failing, and there’s no longer a clear line where legitimate medical research ends and unsound medical research begins (5). More questionable medical research is being published now than ever before in history, including bogus research promoting fake medicines and nutraceuticals. There’s no longer a clear separation between the authentic and counterfeit medical research, even though medical research is the most important research for humankind today. Indeed, of all human endeavours, what surpasses medical research in importance, value, and universal benefit?

Read more 

Fake news/science

The widespread circulation of fake health news on social networks is misleading and potentially dangerous, health officials have warned.
Misinformation published by conspiracy sites about serious health conditions is often shared more widely than evidence-based reports from reputable news organisations, according to analysis by The Independent. Of the 20 most-shared articles on Facebook in 2016 with the word “cancer” in the headline, more than half report claims discredited by doctors and health authorities or – in the case of the year’s top story – directly by the source cited in the article.

In September, a website called healtheternally.com, registered in Phoenix, Arizona, published an article with the headline “Dandelion weed can boost your immune system and cure cancer”. It was the most popular article on Facebook with the word ‘cancer’ in the headline last year, receiving more than 1.4 million shares, likes and comments, according to two separate web analysis tools.
This was around four times as many as the first relevant story from a traditional news website, the New York Times, to appear on the list.
“This potent root builds up blood and immune system – cures prostate, lung, and other cancers better than chemotherapy [sic],” claimed the site, citing research from Dr Carolyn Hamm at the Windsor Regional Cancer Centre in Ontario, Canada.
More than half of last year's 20 most-shared, liked and commented-on news stories with "cancer" in the headline, seen by a combined total of millions, contain claims Cancer Research UK calls “myths” and warns against on its website.
These include a report published by realfarmacy.com claiming body acidity is “the truth behind cancer”, which had 584,000 Facebook engagements, and one headlined “A Secret Has Been Uncovered: Cancer Is Not A Disease But Business!” on newsrescue.com, which had 713,000 Facebook engagements.

Cholesterol and heart disease - some debunking

"Controversial report claims there's no link between 'bad cholesterol' and heart disease," the Daily Mail reports, while The Times states: "Bad cholesterol 'helps you live longer',".
The headlines are based on a new review which aimed to gather evidence from previous observational studies on whether LDL cholesterol (so-called "bad cholesterol") was linked with mortality in older adults aged over 60. The conventional view is that having high LDL cholesterol levels increases your risk of dying of cardiovascular diseases, such as heart disease.
Researchers chose 30 studies in total to analyse. 28 studies looked at the link with death from any cause. Twelve found no link between LDL and mortality, but 16 actually found that lower LDL was linked with higher mortality risk – the opposite to what was expected.
Only nine studies looked at cardiovascular mortality link specifically – seven found no link and two found the opposite link to what was expected.
However, there are many important limitations to this review. This includes the possibility that the search methods may have missed relevant studies, not looking at levels of other blood fats (e.g. total and HDL cholesterol), and the possibility that other health and lifestyle factors are influencing the link.
Most importantly, as the researchers acknowledge, these findings do not take account of statin use, which lowers cholesterol. People found to have high LDL cholesterol at the study's start may have subsequently been started on statins, which could have prevented deaths.  

Where did the story come from?

The study was carried out by researchers from the University of South Florida, the Japan Institute of Pharmacovigilance and various other international institutions in Japan, Sweden, UK, Ireland, US and Italy.
Funding was provided by the Western Vascular Institute. The study was published in the peer-reviewed BMJ Open and, as the journal name suggests, the article is open-access, so can be read for free.
Four of the study authors have previously written book(s) criticising "the cholesterol hypothesis". It should also be noted that nine of the authors are members of THINCS – The International Network of Cholesterol Skeptics. This is described as a group of scientists who "oppose…that animal fat and high cholesterol play a role [in heart disease]".
If you were playing Devil's Advocate, you could argue that this represents a preconceived view of the authors regarding the role of cholesterol, rather than the open, unbiased mind you would hope for in the spirit of scientific enquiry. That said, many important scientific breakthroughs happened due to the efforts of individuals who challenged a prevailing orthodoxy of thinking.
In general, the UK media provided fairly balanced reporting, presenting both sides of the argument – supporting the findings, but with critical views from other experts.

What kind of research was this?

This was a systematic review which aimed to gather evidence from cohort studies to see whether LDL – "bad" – cholesterol is associated with mortality in older adults.
It has long been thought that cholesterol is a key cause of the fatty build-up in arteries (atherosclerosis) that causes heart disease. However, the researchers say there are contradictions to this view. Recent research has suggested that total cholesterol becomes less of a risk factor for all-cause or cardiovascular mortality the older people get. Less is known about LDL specifically and that's what this research aimed to look at.
A systematic review is the best way of gathering evidence from cohort studies that have looked at the link between an exposure or risk factor and an outcome. However, the strength of a review's findings is only as good as the studies they include. In cohort studies, it is often difficult to directly attribute an outcome to a specific cause, and there is always the potential that other factors are influencing the outcome. 

What did the research involve?

The researchers searched one literature database (PubMed) in December 2015 to identify English-language cohort studies that had included a general population sample aged 60 and over. Studies had to have taken baseline measures of LDL cholesterol and then followed participants up over time, looking at the link with all-cause or cardiovascular mortality.
Three authors reviewed potential studies and extracted data. From an initial 2,894 hits, 19 publications, covering 30 cohorts and including 68,094 participants, were included. The majority of studies were excluded outright, as they didn't seem to contain anything relevant in the study title or abstract (summary). The other reasons for exclusion were non-English language, participants not being representative of the general population, not measuring LDL cholesterol at baseline, and not giving separate data for older adults or looking at mortality outcomes.

What were the basic results?

The researchers did not pool the results of the individual cohorts in a meta-analysis, but gave a narrative summary of the findings.
Overall, they reported that 16 cohorts (representing 92% of individuals in the review) of 28 examining all-cause mortality found an inverse relationship between LDL cholesterol and all-cause mortality. That is, as LDL cholesterol went down, all-cause mortality went up – higher LDL was apparently linked to lower all-cause mortality. In 14 of these 16, this was said to be a statistically significant link. The remaining 12 cohorts found no link with all-cause mortality.
Only nine of the identified cohorts specifically reported cardiovascular mortality. Seven found no link between LDL cholesterol and cardiovascular mortality. The other two found that those in the lowest fourth (quartile) of LDL levels actually had the highest cardiovascular mortality.

How did the researchers interpret the results?

The researchers concluded that, "High LDL-C is inversely associated with mortality in most people over 60 years". They said their finding contradicts the cholesterol hypothesis: that cholesterol, particularly LDL, causes fatty build-up in the arteries. 
They consider that as they found older adults with high LDL live just as long as those with low LDL, this "provides the rationale for a re-evaluation of guidelines recommending pharmacological reduction of LDL-C in the elderly".

Conclusion

This research suggests that – contrary to common belief – LDL cholesterol is not as "bad" as may be thought, and higher levels are not linked to all-cause or cardiovascular mortality.
However, before accepting this as fact, there are many important limitations to consider – both to the review and the included studies – many of which the review authors themselves acknowledge:
  • There is the potential that many studies relevant to this question may have been missed out. The review searched only a single literature database, excluded studies only available in non-English language, and excluded studies where the title and abstract did not appear to contain information on the link between LDL and mortality in older adults.
  • The study only looked at the link in older adults aged over 60. LDL-cholesterol levels may show different links with long-term mortality in younger adults. Though this was intended to represent the general older-age population, some studies had excluded people with specific conditions such as dementia, diabetes or terminal illness.
  • The studies varied widely in adjustment for confounding factors that could be having an influence on the link between LDL and mortality. Age, gender and body mass index (BMI) were common factors that studies took into account, but others variably accounted for lifestyle factors (e.g. smoking, alcohol), socioeconomic factors, presence of conditions, and use of medications.
  • Only LDL cholesterol was examined. Levels of total cholesterol, trigylcerides, and the ratio of LDL to HDL "good" cholesterol could be having an effect and mediating the link between LDL and mortality.
  • Most of the evidence for this review is for the link with all-cause mortality – not cardiovascular mortality. High LDL-cholesterol is believed to be linked with the development of atherosclerosis and cardiovascular disease. This review does not provide enough firm evidence to refute this link. The review cannot with certainty explain the reasons for the apparent link between LDL levels and death from any cause – with roughly half of studies finding a link and half not.
  • Importantly, the study does not provide evidence that statins are "a waste of time". These are not trials examining mortality between people prescribed statins or not. The researchers openly acknowledge that the use of statins – which they haven't directly examined – may be confounding the links in these studies. For example, the people found to have the highest LDL cholesterol levels at the study's start may have then been started on statins, and this could have dramatically cut their reduced mortality risk.
The findings of this review and possible explanations will need to be explored further, but for now this review doesn't provide solid evidence that high LDL cholesterol is good for you, or that statins are of no help. People given statins should continue to take them as prescribed.
"Fat is actually good for you" may be a great headline for a newspaper, and there are always researchers who are willing to make such a case, as we saw with the recent National Obesity Forum report.
These types of stories are often based on a selective view of evidence, rather than a comprehensive systematic review. There is currently no comprehensive body of evidence that contradicts current official advice on saturated fat consumption – which recommends no more than 30g of saturated fat a day for men and 20g for women.
Analysis by Bazian. Edited by NHS ChoicesFollow NHS Choices on TwitterJoin the Healthy Evidence forum.

Fake science

Sharyl: Our cover story this week may lead you to question much of what you hear and read about scientific and medical studies. It's a cautionary note issued by respected industry leaders who say unseen interests are exerting enormous control over research and what is or isn't published. Their startling claim: that a large percentage of articles in prestigious medical journals are simply not to be believed. We begin with Dr. Marcia Angell of Harvard, a pioneer in the medical journal field.
Dr. Marcia Angell: I think physicians and the public have come to believe that drugs are much better and much safer than they really are.
Sharyl: What makes Dr. Marcia Angell’s skepticism so remarkable is where she places much of the blame: on researchers and medical journals.
Sharyl: That includes the prestigious New England Journal of Medicine where she worked for 20 years and was its first female editor in chief from 1999 to 2000.
Sharyl: Most people probably think an article is in a journal, probably written at a university probably based on independent study, and that's that.